|
시장보고서
상품코드
1890955
부비동염 치료제 시장 : 약물 종류별, 투여 경로별, 제형별, 처방 상황별, 환자 연령층별, 질환 유형별, 유통 채널별, 최종사용자별, 지역별Sinusitis Drugs Market, By Drug Class, By Route of Administration, By Dosage Form, By Prescription Status, By Patient Age Group, By Disease Type, By Distribution Channel, By End User, By Geography |
||||||
부비동염 치료제 시장은 2025년에 31억 1,000만 달러로 추정되며, 2032년까지 47억 4,000만 달러에 달할 것으로 예측됩니다. 2025-2032년까지 CAGR 6.2%로 성장할 전망입니다.
| 보고서 내용 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2024년 | 2025년 시장 규모: | 31억 1,000만 달러 |
| 과거 데이터 대상 기간: | 2020-2024년 | 예측 기간: | 2025-2032년 |
| 예측 기간 2025-2032년: | 6.20% | 2032년 예측치: | 47억 4,000만 달러 |
세계 부비동염 치료제 시장은 제약 산업에서 중요한 부분을 차지하고 있으며, 전 세계 수백만 명의 사람들에게 영향을 미치는 가장 흔한 호흡기질환 중 하나를 다루고 있습니다. 부비동의 염증을 특징으로 하는 부비동염은 급성 및 만성 형태로 나타나며, 효과적인 치료 약물 개입에 대한 큰 수요를 창출하고 있습니다.
이 질환은 전 세계 인구의 약 12-15%가 매년 앓고 있으며, 만성 부비동염은 삶의 질을 떨어뜨리고 의료비 부담이 큰 질환입니다. 시장에는 항생제, 코르티코스테로이드, 충혈제거제, 항히스타민제, 부비동 염증의 기저에 있는 다양한 병태생리학적 기전을 다루기 위해 고안된 새로운 표적 치료제 등 다양한 치료제가 있습니다.
호흡기 알레르기의 증가, 환경오염, 생활습관 요인 등이 발병률 상승에 기여하고 있으며, 특히 도시 거주자에서 두드러집니다. 시장 환경은 환자의 복약 순응도와 치료 효과를 높이기 위한 비강용액, 경구용 제제, 첨단 세척 솔루션 등 혁신적인 약물전달 시스템으로 진화하고 있습니다. 의료 서비스 제공자들은 생산성 저하, 의료 서비스 반복 이용 등 치료되지 않은 부비동염이 미치는 경제적 영향을 점점 더 많이 인식하고 있으며, 이는 보다 효과적인 치료법에 대한 수요를 촉진하고 있습니다.
시장 역학
세계 부비동염 치료제 시장은 치료제 부문 전반에 걸쳐 견조한 성장 기회를 창출하는 여러 주요 촉진요인에 의해 주도되고 있습니다. 주요 촉진요인은 대기 오염 수준의 증가, 도시화, 부비동 염증을 유발하는 호흡기 알레르기의 증가로 인한 전 세계 부비동염 질환의 유병률 증가에 기인합니다.
헬스케어 인식 제고 캠페인과 진단 기술의 향상으로 조기 발견 및 조기 치료가 가능해지면서 의약품 개입을 원하는 환자층이 확대되고 있습니다. 세계 인구의 고령화도 중요한 성장 요인이며, 노인은 만성 부비동염 및 관련 합병증에 대한 감수성이 높아집니다. 그러나 시장에는 성장 궤도를 저해하는 뚜렷한 제약도 존재합니다.
제네릭 의약품의 보급은 브랜드 의약품에 가격 압박을 가져오고, 엄격한 규제 승인 절차는 혁신적인 치료법의 시장 진입을 지연시킵니다. 또한, 외과적 개입 및 대체의학 접근법을 포함한 비약물적 치료법에 대한 선호는 특정 환자군에서 의약품 시장 확대를 제한할 수 있습니다. 또한, 특히 세균성 부비동염의 경우 항생제 내성에 대한 우려가 배합 패턴을 제한하고 있습니다.
이러한 도전에도 불구하고, 시장 상황에는 큰 기회가 존재합니다. 특정 염증 채널을 표적으로 하는 치료법 개발은 연구개발에 투자하는 제약회사에게 수익성 높은 전망을 가져다 줄 수 있습니다. 아시아태평양 및 라틴아메리카 신흥시장에서는 의료 인프라 개선과 의료비 지출 증가로 인해 미개발된 성장 잠재력이 기대되고 있습니다.
본 조사의 주요 특징
- 세계의 부비동염 치료제 시장에 대해 조사분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 동안 시장 규모(10억 달러)와 CAGR(연평균 성장률)을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 촉진요인, 억제요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 정보도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계 부비동염 치료제 시장의 주요 기업을 프로파일링합니다. 회사 개요,제품 포트폴리오,주요 하이라이트,재무 실적,전략
- 이 보고서는 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 부비동염 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 부비동염 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것으로 보입니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 범위
- 보고서 개요
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porters 분석
- 인수합병 동향
- 산업 동향
제4장 세계의 부비동염 치료제 시장 : 약물 종류별, 2020-2032년
- 항생제
- 코르티코스테로이드
- 항히스타민제
- 충혈제거제
- 진통제/통증 완화제
- 항진균제
- 생리식염수 점비약
- 면역치료제
제5장 세계의 부비동염 치료제 시장 : 투여 경로별, 2020-2032년
- 경구
- 비강내(스프레이/점비약)
- 비경구(주사/점적)
- 국소
제6장 세계의 부비동염 치료제 시장 : 제형별, 2020-2032년
- 정제
- 캡슐
- 스프레이
- 점안제
- 시럽·액제
- 흡입기
제7장 세계의 부비동염 치료제 시장 : 처방 상황별, 2020-2032년
- 처방약(Rx)
- 시판약(OTC)
제8장 세계의 부비동염 치료제 시장 : 환자 연령층별, 2020-2032년
- 소아
- 성인
- 노인
제9장 세계의 부비동염 치료제 시장 : 질환 유형별, 2020-2032년
- 급성 부비동염
- 아 급성 부비동염
- 만성 부비동염
제10장 세계의 부비동염 치료제 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 부비동염 치료제 시장 : 최종사용자별, 2020-2032년
- 병원
- 클리닉
- 재택의료 시설
- 전문 센터
제12장 세계의 부비동염 치료제 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제13장 경쟁 구도
- Pfizer Inc
- GlaxoSmithKline plc
- Sanofi
- Regeneron Pharmaceuticals Inc
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Bayer AG
- Merck & Co Inc
- Hoffmann La Roche Ltd
- AbbVie Inc
- Teva Pharmaceutical Industries Ltd
- Allergan plc(현AbbVie 산하)
- Sun Pharmaceutical Industries Ltd
- Dr Reddys Laboratories Ltd
제14장 애널리스트의 추천사항
- 기회
- Coherent Opportunity Map
제15장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Sinusitis Drugs Market is estimated to be valued at USD 3.11 Bn in 2025 and is expected to reach USD 4.74 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.11 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.20% | 2032 Value Projection: | USD 4.74 Bn |
The global sinusitis drugs market represents a critical segment within the pharmaceutical industry, addressing one of the most prevalent respiratory conditions affecting millions of individuals worldwide. Sinusitis, characterized by inflammation of the paranasal sinuses, manifests in acute and chronic forms, creating substantial demand for effective therapeutic interventions.
The condition affects approximately 12-15% of the global population annually, with chronic sinusitis impacting quality of life and imposing significant healthcare burdens. The market encompasses various therapeutic classes including antibiotics, corticosteroids, decongestants, antihistamines, and emerging targeted therapies designed to address different pathophysiological mechanisms underlying sinus inflammation.
Rising prevalence of respiratory allergies, environmental pollution, and lifestyle factors contribute to increased incidence rates, particularly in urban populations. The market landscape is evolving with innovative drug delivery systems, including nasal sprays, oral formulations, and advanced irrigation solutions, aimed at improving patient compliance and therapeutic outcomes. Healthcare providers increasingly recognize the economic impact of untreated sinusitis, including productivity losses and recurrent healthcare utilization, driving demand for more effective treatment options.
Market Dynamics
The global sinusitis drugs market is propelled by several key drivers that create robust growth opportunities across therapeutic segments. The primary driver stems from increasing prevalence of sinusitis conditions worldwide, attributed to rising air pollution levels, urbanization, and growing incidence of respiratory allergies that predispose individuals to sinus inflammation.
Healthcare awareness campaigns and improved diagnostic capabilities enable earlier detection and treatment initiation, expanding the patient pool seeking pharmaceutical interventions. The aging global population represents another significant growth driver, as elderly individuals demonstrate higher susceptibility to chronic sinusitis and related complications. However, the market faces notable restraints that could impede growth trajectories.
Generic drug penetration poses pricing pressures on branded pharmaceutical products, while stringent regulatory approval processes delay market entry of innovative therapies. Additionally, the preference for non-pharmacological treatments, including surgical interventions and alternative medicine approaches, may limit pharmaceutical market expansion in certain patient populations. Antibiotic resistance concerns also restrict prescribing patterns, particularly for bacterial sinusitis cases.
Despite these challenges, substantial opportunities exist within the market landscape. The development of targeted therapies addressing specific inflammatory pathways presents lucrative prospects for pharmaceutical companies investing in research and development. Emerging markets in Asia-Pacific and Latin America offer untapped growth potential due to improving healthcare infrastructure and increasing healthcare expenditure.
Key Features of the Study
- This report provides in-depth analysis of the global sinusitis drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sinusitis drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, GlaxoSmithKline plc, Sanofi, Regeneron Pharmaceuticals Inc, AstraZeneca plc, Novartis AG, Johnson and Johnson, Bayer AG, Merck and Co Inc, F. Hoffmann La Roche Ltd, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Allergan plc (now part of AbbVie), Sun Pharmaceutical Industries Ltd, and Dr Reddys Laboratories Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sinusitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sinusitis drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antibiotics
- Corticosteroids
- Antihistamines
- Decongestants
- Analgesics/Pain Relievers
- Antifungal Agents
- Saline Nasal Sprays
- Immunotherapy Drugs
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Nasal (Spray / Drops)
- Parenteral (Injection / IV)
- Topical
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets
- Capsules
- Sprays
- Drops
- Syrups/Liquids
- Inhalers
- Prescription Status Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription-only (Rx)
- Over-the-counter (OTC)
- Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Disease Type Insights (Revenue, USD Bn, 2020 - 2032)
- Acute Sinusitis
- Subacute Sinusitis
- Chronic Sinusitis
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Clinics
- Homecare Settings
- Specialty Centers
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- GlaxoSmithKline plc
- Sanofi
- Regeneron Pharmaceuticals Inc
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Bayer AG
- Merck & Co Inc
- Hoffmann La Roche Ltd
- AbbVie Inc
- Teva Pharmaceutical Industries Ltd
- Allergan plc (now part of AbbVie)
- Sun Pharmaceutical Industries Ltd
- Dr Reddys Laboratories Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Sinusitis Drugs Market, By Drug Class
- Global Sinusitis Drugs Market, By Route of Administration
- Global Sinusitis Drugs Market, By Dosage Form
- Global Sinusitis Drugs Market, By Prescription Status
- Global Sinusitis Drugs Market, By Patient Age Group
- Global Sinusitis Drugs Market, By Disease Type
- Global Sinusitis Drugs Market, By Distribution Channel
- Global Sinusitis Drugs Market, By End User
- Global Sinusitis Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Sinusitis Drugs Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Analgesics/Pain Relievers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antifungal Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Saline Nasal Sprays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Sinusitis Drugs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal (Spray / Drops)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral (Injection / IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Sinusitis Drugs Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sprays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Syrups/Liquids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Sinusitis Drugs Market, By Prescription Status, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription-only (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-counter (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Sinusitis Drugs Market, By Patient Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Sinusitis Drugs Market, By Disease Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Acute Sinusitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subacute Sinusitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic Sinusitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Sinusitis Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Sinusitis Drugs Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Sinusitis Drugs Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan plc (now part of AbbVie)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddys Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
